Legend Biotech opens a 31,000-square-foot R&D facility in Philadelphia to enhance its cell therapy research capabilities.
Quiver AI Summary
Legend Biotech Corporation has officially opened a new 31,000-square-foot research and development facility in Philadelphia, aimed at enhancing its U.S. operations and strengthening its role in cell therapy innovation. This state-of-the-art facility will focus on research and development for CAR-T therapies targeting oncology and immunology, fostering collaboration and innovation through advanced labs and workspaces. The opening of this site is celebrated as a significant milestone for Legend, which employs over 1,400 people in the U.S. and complements its existing R&D efforts in New Jersey. Local officials and community members welcomed the expansion, recognizing its potential to contribute to Philadelphia's life sciences ecosystem and overall healthcare innovation.
Potential Positives
- The opening of a new 31,000-square-foot R&D facility in Philadelphia enhances Legend Biotech's U.S. research footprint, demonstrating the company’s commitment to growth and innovation.
- This facility is strategically positioned to support the development of CAR-T therapies, which are critical in the oncology and immunology fields, underscoring the company’s leadership in cell therapy.
- The expansion is expected to create approximately 55 new jobs, contributing to the local economy and strengthening Legend’s workforce in a key biotech hub.
- The site will foster collaborations with local research institutions and leverage Philadelphia’s reputation as a leader in life sciences, which can lead to accelerated innovation and research advancements.
Potential Negatives
- Expansion of the R&D facility may signal previous limitations in existing capabilities or operational issues at current locations.
- Significant reliance on the successful development of CAR-T therapies could pose risks, especially in light of uncertainties in clinical trials and regulatory processes.
- Forward-looking statements indicate potential vulnerabilities in future plans that are contingent on various external factors, which could impact stockholder confidence.
FAQ
What is the purpose of Legend Biotech's new R&D facility?
The facility supports advancing CAR-T research for oncology and immunology, enhancing Legend Biotech's cell therapy innovations.
Where is the new Legend Biotech facility located?
The new facility is located at 2300 Market Street, Philadelphia, Pennsylvania.
How many employees will the Philadelphia facility have?
Approximately 55 full-time team members will be employed at the new Philadelphia facility.
What innovative therapies is Legend Biotech known for?
Legend Biotech is pioneering CAR-T cell therapy, particularly with its treatment CARVYKTI® for multiple myeloma.
Why did Legend Biotech choose Philadelphia for expansion?
Philadelphia offers a strong life sciences ecosystem and access to top-tier talent and research institutions.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LEGN Hedge Fund Activity
We have seen 101 institutional investors add shares of $LEGN stock to their portfolio, and 114 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 12,466,098 shares (+94.4%) to their portfolio in Q2 2025, for an estimated $442,421,818
- PRICE T ROWE ASSOCIATES INC /MD/ removed 5,929,559 shares (-88.1%) from their portfolio in Q2 2025, for an estimated $210,440,048
- DEERFIELD MANAGEMENT COMPANY, L.P. added 2,962,338 shares (+inf%) to their portfolio in Q2 2025, for an estimated $105,133,375
- INVESCO LTD. removed 2,919,873 shares (-99.4%) from their portfolio in Q2 2025, for an estimated $103,626,292
- WELLINGTON MANAGEMENT GROUP LLP removed 1,857,268 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $65,914,441
- BALYASNY ASSET MANAGEMENT L.P. added 746,642 shares (+371.5%) to their portfolio in Q2 2025, for an estimated $26,498,324
- MORGAN STANLEY removed 613,827 shares (-54.2%) from their portfolio in Q2 2025, for an estimated $21,784,720
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$LEGN Analyst Ratings
Wall Street analysts have issued reports on $LEGN in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Cantor Fitzgerald issued a "Overweight" rating on 11/13/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/17/2025
- RBC Capital issued a "Outperform" rating on 08/12/2025
- Morgan Stanley issued a "Overweight" rating on 08/12/2025
- UBS issued a "Buy" rating on 07/02/2025
To track analyst ratings and price targets for $LEGN, check out Quiver Quantitative's $LEGN forecast page.
$LEGN Price Targets
Multiple analysts have issued price targets for $LEGN recently. We have seen 7 analysts offer price targets for $LEGN in the last 6 months, with a median target of $75.0.
Here are some recent targets:
- Eric Schmidt from Cantor Fitzgerald set a target price of $75.0 on 11/13/2025
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $60.0 on 10/17/2025
- Jessica Fye from JP Morgan set a target price of $76.0 on 10/09/2025
- Leonid Timashev from RBC Capital set a target price of $77.0 on 08/12/2025
- Matthew Harrison from Morgan Stanley set a target price of $83.0 on 08/12/2025
- Ashwani Verma from UBS set a target price of $54.0 on 07/02/2025
Full Release
31,000-square-foot site expands Legend’s U.S. R&D footprint and strengthens its position as a global leader in cell therapy innovation
The facility will support CAR-T R&D in potential oncology and immunology indications
A Media Snippet accompanying this announcement is available by clicking on this link.
SOMERSET, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a U.S.-based global leader in cell therapy, today announced the official opening and ribbon cutting of its new, state-of-the-art research and development (R&D) facility in Philadelphia, Pennsylvania.
Located at 2300 Market Street, the 31,000-square-foot facility is now fully operational and will support Legend’s expanding pipeline of next-generation cell therapies. The site features cutting-edge laboratories and collaborative workspaces designed to foster innovation and accelerate research programs across Legend’s oncology and immunology portfolios.
“This new facility marks an exciting milestone for Legend Biotech as we continue to invest in our future and strengthen our leadership in cell therapy innovation,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “We are proud to officially open our doors in Philadelphia, a world-class hub for life sciences, where we can attract top-tier talent, collaborate with premier research institutions, and advance our mission to bring transformative therapies to patients.”
The Philadelphia R&D center expands Legend’s American presence, which includes over 1,400 employees in the United States. The site will employ approximately 55 full-time team members and complements Legend’s existing R&D presence in Piscataway, New Jersey. Headquartered in Somerset, N.J., Legend also has manufacturing activities in Raritan and Morris Plains, N.J.
“The opening of our new facility represents an exciting new chapter for our research organization,” said Guowei Fang, Ph.D., President of Research and Development at Legend Biotech. “Our Philadelphia team will play a critical role in advancing our sustainable pipeline of innovative cell therapies, while strengthening collaborations within one of the nation’s most dynamic biotech ecosystems.”
Local officials, academic partners, patient advocacy groups, and members of the Philadelphia biotech community gathered with Legend Biotech leadership to celebrate the ribbon-cutting ceremony and tour the new facility.
“Legend Biotech’s decision to expand its R&D footprint in Philadelphia reflects the strength and momentum of our city’s life sciences ecosystem,” said Dr. Rebecca L. Grant, Director of Life Sciences & Innovation for the City of Philadelphia’s Department of Commerce. “Philadelphia is home to world-class scientific talent and research institutions, and we are proud to welcome an organization committed to pioneering therapies that change patient lives. We look forward to supporting Legend Biotech as they grow here and contribute to the continued advancement of cell and gene therapy innovation in our city.”
“Philadelphia continues to be a magnet for innovation and scientific excellence,” said Chris Molineaux, CEO of Life Sciences Pennsylvania. “We are thrilled to welcome Legend Biotech to our city’s thriving life sciences community. Their investment brings high-quality jobs, research opportunities, and further reinforces Philadelphia’s growing reputation as a global leader in healthcare innovation.”
About Legend Biotech
With over 2,900 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI
®
, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. To date, CARVYKTI has been administered to over 9,000 patients with multiple myeloma at 132 treatment centers spanning 44 states across the U.S. Headquartered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.
Learn more at www.legendbiotech.com and follow us on LinkedIn .
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives, and the potential benefits of Legend Biotech’s product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third-party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 11, 2025. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated, or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
[email protected]
PRESS CONTACT:
Alexandra Ventura
Tel: (732) 850-5598
[email protected]
